Nonmedical Use of Xtampza® ER and Other Oxycodone Medications in Adults Evaluated for Substance Abuse Treatment: Real-World Data from the Addiction Severity Index-Multimedia Version (ASI-MV®)
Authors:
- Jody L GreenJGJody L Green
- Rebekkah S RobbinsRRRebekkah S Robbins
- Taryn Dailey-GovoniTDTaryn Dailey-Govoni
- Stephen F ButlerSBStephen F Butler
Open Access
- 1 June 2021
- journal article
- research article
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 14, 1773-1783
Abstract
Purpose: The purpose of this study was to evaluate real-world data related to past 30-day nonmedical use (NMU) and routes of administration of Xtampza® ER and comparator oxycodone medications in the US as captured within the Addiction Severity Index-Multimedia Version® (ASI-MV®). Methods: Data were collected from July 2016 through December 2019 from 647 centers located in 44 states using the ASI-MV, a clinical instrument used to evaluate substance use and treatment planning. Demographic characteristics were assessed using Pearson’s chi-square test for categorical data and quarterly NMU rates were calculated. Distribution of route of administration was studied using a proportional reporting ratio (PRR) analysis. Results: Of 192,810 assessments, 42,279 (21.9%) indicated past 30-day NMU of at least one prescription opioid, including Xtampza ER (N=73, 0.2%), other oxycodone ER (n=3802, 9.0%) and oxycodone IR (n=14,579, 34.5%). All quarterly Xtampza ER NMU rates per 100 ASI-MV assessments were significantly lower than those for other oxycodone ER and oxycodone IR. Overall, quarterly Xtampza ER NMU drug utilization adjusted rates were significantly lower than quarterly rates observed for other oxycodone ER NMU but not consistently significantly lower than oxycodone IR NMU. Although not all statistically significant, all ratios from the PRR analysis were less than 1.0, indicating that rates of use of any alternate route, any non-oral route, snorting, and injecting were higher for other oxycodone ER and oxycodone IR than for Xtampza ER. Conclusion: Xtampza ER had significantly lower rates of NMU than other oxycodone ER products and oxycodone IR products, as well as significantly lower rates of non-oral NMU than oxycodone IR products, in a population of individuals seeking substance abuse treatment. Understanding risks associated with different opioid medications is important for prescribers as they manage risks of opioid misuse and abuse with effective pain therapy.Keywords
This publication has 20 references indexed in Scilit:
- Effect of physical manipulation on the oral pharmacokinetic profile of Xtampza® ER (oxycodone DETERx® formulation): A review of published studiesJournal of Opioid Management, 2020
- Efficacy of opioids versus placebo in chronic pain: a systematic review and meta-analysis of enriched enrollment randomized withdrawal trialsJournal of Pain Research, 2018
- In Vitro Drug Release After Crushing: Evaluation of Xtampza® ER and Other ER Opioid FormulationsClinical Drug Investigation, 2017
- The Comparative Pharmacokinetics of Physical Manipulation by Crushing of Xtampza ® ER Compared with OxyContin ®Pain Management, 2017
- Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administrationDrug and Alcohol Dependence, 2017
- Oral Human Abuse Potential of Oxycodone DETERx®(Xtampza®ER)The Journal of Clinical Pharmacology, 2016
- In vitro assessment of the potential for abuse via the intravenous route of oxycodone DETERx® microspheresJournal of Opioid Management, 2016
- Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent PropertiesPain Medicine, 2015
- Rates of opioid misuse, abuse, and addiction in chronic painPain, 2015
- Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: An extended-release, abuse-deterrent formulationJournal of Opioid Management, 2014